Cellectar Biosciences Investor Relations Material
Latest events
Q4 2024
Cellectar Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cellectar Biosciences Inc
Access all reports
Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
CLRB
Country
🇺🇸 United States